Castrate-resistant Prostate Cancer (CRPC) Market

Castrate-resistant Prostate Cancer (CRPC) Market Analysis and Forecast by Fact.MR

• The global castrate-resistant prostate cancer market covers pharmaceutical therapies used to treat prostate cancer that continues to progress despite castrate-level testosterone suppression.
• Therapy categories include next-generation hormonal agents, chemotherapy, targeted radiopharmaceuticals, immunotherapy, and PARP inhibitors.
• These products are administered through hospitals, specialty oncology clinics, and ambulatory infusion centers.
• Growth is shaped by rising prostate cancer incidence, expanding use of biomarker-guided treatment selection, and increasing availability of combination regimens for metastatic CRPC.

Summary of Castrate-resistant Prostate Cancer (CRPC) Market

• Market Snapshot
  • In 2025, the global Castrate-resistant Prostate Cancer (CRPC) Market was valued at approximately USD 14.1 billion.
  • The market is estimated to reach USD 15.3 billion in 2026 and is projected to attain USD 34.59 billion by 2036.
  • The castrate-resistant prostate cancer (crpc) market is likely to expand at a CAGR of 8.5% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 19.29 billion between 2026 and 2036.
  • Hormonal Therapy accounts for 42% of therapy share in 2026.
  • India (9.6%) and China (9.4%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Growing number of prostate cancer patients progressing to castration-resistant disease is expanding the addressable treatment population.
  • Expanding availability of next-generation hormonal agents including enzalutamide, abiraterone, and darolutamide is increasing treatment options and prescription volumes.
  • Rising adoption of biomarker-guided therapy selection, including BRCA and HRR testing, is enabling targeted treatment with PARP inhibitors and expanding market segmentation.
  • Increasing use of combination regimens that pair hormonal therapy with chemotherapy or radiopharmaceuticals is extending treatment duration and per-patient spending.
  • Growing clinical evidence supporting earlier intervention with advanced therapies in mCRPC is shifting treatment initiation toward more aggressive protocols.
• Product and Segment View
  • Hormonal Therapy accounts for 42% of the therapy segment in 2026, supported by broad applicability across primary end-use categories.
  • Metastatic CRPC represents 61% of the application segment in 2026, reflecting sustained institutional demand.
  • Key segmentation includes: Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Radiotherapy, Other Emerging Therapies. Product: Hormonal Therapy, Androgen Synthesis Inhibitors, Chemotherapy, Non Taxane Chemotherapy, Immunotherapy, Immune Checkpoint Inhibitors, Radiotherapy, External Beam Radiotherapy, Targeted Therapy, Kinase Inhibitors. Application: Metastatic Castrate Resistant Prostate Cancer, Visceral Metastasis, Non Metastatic Castrate Resistant Prostate Cancer, Early Stage Resistant Cases. End Use: Hospitals, Cancer Treatment Centers, Ambulatory Care Centers, Research Institutes. Technology: Drug Therapy, Precision Medicine, Radiopharmaceutical Technology, Immuno Oncology Technology.
• Geography and Competitive Outlook
  • North America maintains a leading position supported by established healthcare infrastructure and strong institutional procurement.
  • Europe shows steady demand driven by regulatory frameworks, clinical standards, and aging demographics.
  • Asia Pacific is the fastest-growing region, led by India (9.6%) and China (9.4%).
  • Key players include Johnson & Johnson Services, Inc., Sanofi S.A., Pfizer Inc., Astellas Pharma Inc., Bayer AG, AstraZeneca plc.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The CRPC market is being reshaped by precision medicine. Biomarker-guided treatment selection is no longer optional but a standard component of mCRPC management. PARP inhibitors for BRCA-mutated patients and radiopharmaceuticals like Lu-177 PSMA are creating new treatment segments that did not exist five years ago. The commercial opportunity is in companion diagnostic and therapy pairings that lock in prescribing patterns and create long-term treatment relationships.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising disease prevalence and aging populations are expanding the addressable patient population requiring specialized products.
• Increasing institutional adoption and clinical guideline integration are supporting procurement growth in hospital and long-term care settings.
• Expanding healthcare infrastructure in developing economies is creating new procurement demand across emerging market facilities.

Key Market Constraints

• Cost sensitivity in price-constrained healthcare settings limits adoption of premium products.
• Limited clinical awareness in certain markets restricts demand growth for specialized products.
• Regulatory differences across countries create compliance complexity for manufacturers.

Key Opportunity Areas

• Development of integrated care kits combining multiple product categories creates higher-value procurement opportunities.
• Expansion of homecare programs opens new demand channels beyond traditional institutional settings.
• Product innovation in safety, monitoring, and ease-of-use features supports premiumization.

Segment-wise Analysis of the Castrate-resistant Prostate Cancer (CRPC) Market

• Hormonal Therapy holds 42% of the therapy segment in 2026.
• Metastatic CRPC represents 61% of the application segment in 2026.

The castrate-resistant prostate cancer (crpc) market is segmented by therapy, product, application, end use, technology, and region.

Which Therapy Segment Dominates the Castrate-resistant Prostate Cancer (CRPC) Market?

Hormonal Therapy is expected to account for approximately 42% of the therapy segment in 2026. This leadership reflects sustained demand from primary use cases, established procurement patterns, and broad applicability across key end-use categories.

Other segments within this category serve specialized requirements and contribute to overall market diversification. Competition across segments is shaped by product performance, pricing, and alignment with institutional procurement standards.

Which Application Segment Dominates the Castrate-resistant Prostate Cancer (CRPC) Market?

Metastatic CRPC is expected to account for approximately 61% of the application segment in 2026. Demand is shaped by institutional procurement requirements, clinical adoption patterns, and established end-use applications.

Remaining segments serve specific clinical, demographic, or application needs, each contributing to the overall market through differentiated demand drivers and procurement channels.

Which Product Trend is Shaping the Next Phase of Growth in the Castrate-resistant Prostate Cancer (CRPC) Market?

Radioligand therapies targeting PSMA-expressing tumors are emerging as the most significant treatment advancement in the CRPC space. Their adoption is projected to rise as oncologists shift toward targeted radiopharmaceuticals that deliver radiation directly to cancer cells while sparing surrounding tissue. This is particularly relevant for metastatic CRPC patients who have progressed through hormonal therapy and chemotherapy.

The shift toward radioligand therapies reflects a broader change in CRPC treatment sequencing. Oncologists are moving from sequential single-agent therapy toward precision-targeted approaches guided by PSMA imaging and molecular biomarkers. As a result, radiopharmaceutical treatment capacity is expanding in nuclear medicine departments, and companies with integrated diagnostic-therapeutic platforms are capturing premium pricing in the advanced CRPC treatment segment.

Regional Outlook Across Key Markets

• India leads growth at 9.6%, supported by expanding healthcare infrastructure and rising demand for specialized products.
• China follows at 9.4%, driven by government healthcare programs and increasing clinical adoption.
• Mature markets show steady growth supported by established healthcare systems and replacement demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Castrate-resistant Prostate Cancer (CRPC) in India

The India castrate-resistant prostate cancer (crpc) market is projected to grow at a CAGR of 9.6% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Demand Trends in Castrate-resistant Prostate Cancer (CRPC) in China

The China castrate-resistant prostate cancer (crpc) market is projected to grow at a CAGR of 9.4% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Growth Assessment for Castrate-resistant Prostate Cancer (CRPC) in USA

The USA castrate-resistant prostate cancer (crpc) market is projected to grow at a CAGR of 8.7% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Market Analysis of Castrate-resistant Prostate Cancer (CRPC) in Japan

The Japan castrate-resistant prostate cancer (crpc) market is projected to grow at a CAGR of 8.5% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Opportunity Outlook for Castrate-resistant Prostate Cancer (CRPC) in France

The France castrate-resistant prostate cancer (crpc) market is projected to grow at a CAGR of 8.5% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Competitive Benchmarking and Company Positioning

Castrate-resistant Prostate Cancer (CRPC) Market Analysis By Company

• Johnson & Johnson Services, Inc., Sanofi S.A., Pfizer Inc. hold strong positions through broad portfolios and established distribution networks.
• Astellas Pharma Inc., Bayer AG, AstraZeneca plc compete across specific segments, price tiers, and regional markets.
• Competition is shaped by product quality, clinical evidence, pricing, and distribution capabilities.

The competitive landscape is moderately fragmented, with established medical companies competing alongside specialized manufacturers. Product quality, clinical evidence, and service support drive purchasing decisions.

Strategic priorities include expanding product portfolios, strengthening distribution networks, and developing service-linked revenue models.

Key Companies in the Castrate-resistant Prostate Cancer (CRPC) Market

Johnson & Johnson Services, Inc., Sanofi S.A., Pfizer Inc., Astellas Pharma Inc. are among the leading players. Bayer AG, AstraZeneca plc, Novartis AG, Merck & Co., Inc. hold established positions. Bristol-Myers Squibb Company, Roche Holding AG compete through focused product offerings.

Recent Industry Developments

• Johnson & Johnson Services, Inc. - Product Portfolio Expansion (January 2026)
  • Johnson & Johnson Services, Inc. expanded its product portfolio targeting growing demand segments.
• Sanofi S.A. - Market Expansion (2025)
  • Sanofi S.A. broadened geographic presence through distribution partnerships.
• Pfizer Inc. - Technology Enhancement (2025)
  • Pfizer Inc. introduced technology improvements targeting performance and compliance.

Leading Companies Shaping the Castrate-resistant Prostate Cancer (CRPC) Market

• Johnson & Johnson Services, Inc.
• Sanofi S.A.
• Pfizer Inc.
• Astellas Pharma Inc.
• Bayer AG
• AstraZeneca plc
• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb Company
• Roche Holding AG

Sources and Research References

• Johnson & Johnson Services, Inc.. Product portfolio and corporate updates.
• Sanofi S.A.. Product launches and market announcements.
• World Health Organization. Disease prevalence and healthcare infrastructure data.
• Primary interviews with manufacturers, distributors, clinicians, and end users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Castrate-resistant Prostate Cancer (CRPC) Market?
• How fast is the market expected to grow between 2026 and 2036?
• Which therapy is likely to lead the market by 2026?
• Which application segment accounts for the highest demand?
• What factors are driving demand globally?
• Which countries show the fastest growth through 2036?
• Who are the key companies in the Castrate-resistant Prostate Cancer (CRPC) Market?
• How does Fact.MR estimate and validate the forecast?
• What are the key constraints and opportunities?
• How is product innovation influencing growth?

Castrate-resistant Prostate Cancer (CRPC) Market Definition

The CRPC market covers pharmaceutical therapies for treating prostate cancer that progresses despite castrate-level testosterone suppression, including hormonal agents, chemotherapy, radiopharmaceuticals, immunotherapy, and PARP inhibitors.

Castrate-resistant Prostate Cancer (CRPC) Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across key segmentation categories and regions.
• It includes regional demand analysis based on disease prevalence, healthcare spending, institutional procurement patterns, and regulatory frameworks.
• The report covers pricing analysis, competitive landscape, and distribution strategies of leading companies.
• It includes technology trends, product innovation, and emerging market dynamics influencing demand growth.

Castrate-resistant Prostate Cancer (CRPC) Market Exclusions

• The scope excludes products and services outside the defined market boundary serving different clinical or commercial purposes.
• It excludes non-commercial, custom-built, or research-only systems not available through standard procurement.
• The report excludes informal products with limited quality standardization and market visibility.
• It also excludes adjacent categories that differ in product classification and regulatory pathway.

Castrate-resistant Prostate Cancer (CRPC) Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25+ interviews across manufacturers, distributors, and end users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.